Erasca Faces Class Action Lawsuit Following 48% Stock Collapse Over Safety Concerns

Key Facts

1Erasca faces a securities class action lawsuit following a 48% stock drop triggered by drug safety concerns and intellectual property disputes.

Amid escalating challenges in the biotech sector regarding compliance and innovation, Hagens Berman has filed a securities class action lawsuit against Erasca, Inc. following a precipitous drop in its share price. This legal action follows a 48% decline in stock value, representing a loss of $9.25, triggered by serious concerns over drug safety and intellectual property disputes. According to reports, the crisis stems from patent infringement allegations by Revolution Medicines and troubling reports of a patient death shortly after receiving the experimental treatment ERAS-0015.

This case highlights the high-stakes nature of the specialty pharmaceuticals sector, where legal disputes often lead to violent swings in market capitalization; for instance, peers like Revolution Medicines (RVMD) have seen varied price actions based on pipeline developments. Per market data, the ongoing dispute over ERAS-0015 places additional strain on Erasca’s balance sheet, particularly with rising potential litigation costs and uncertainty surrounding regulatory approval timelines.

Regarding market performance, ERAS stock stood at $18.47 (at close July 2, 2026), with a daily trading range between $17.24 and $18.49. Investors are now monitoring for any legal updates from the court regarding the class action, while the immediate economic calendar shows no direct sector-related catalysts, leaving the focus entirely on legal developments and the results of the company's medical reviews.